Creative Bioarray
Located at Long Island, New York, Creative Bioarray was founded as biomedical company focused on providing comprehensive biotechnology and pharmaceutical array services and products for high-throughput analysis. Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.
Innovative Trials
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys ‘boots-on-the-ground’ recruitment experts in over 70 countries, addressing individual sites’…
Company Details
Latest Content from PMHub
Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients
Press Releases | July 30, 2026 | Impetus Digital
True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.
The Heart of the Matter: Medscape Education’s Cardiology Footprint at ESC 2026
Press Releases | July 28, 2026 | Medscape Education
For more than 30 years, Medscape Education has built independent, accredited cardiovascular education designed around one goal: improved patient outcomes. This year at the European Society of Cardiology Congress (ESC...
A seat at the table: what the EU HTA reforms really ask of patient involvement
White Papers and Resources | July 24, 2026 | Cuttsy + Cuttsy
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
What do patient stories actually teach us?
Press Releases | July 21, 2026 | Mednet
How do we translate individual experiences into support that helps others and create support that feels personal but remains relevant to many?
Infographic: Are data blind spots putting your launch at risk?
White Papers and Resources | July 16, 2026 | Inizio
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize...
Key takeaways from ASCO® 2026
White Papers and Resources | July 16, 2026 | Inizio
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
More Than Pink Walls: What Women-Centric Care Actually Requires
Press Releases | July 15, 2026 | Medscape Education
The phrase "patient-centered care" is tossed around freely in healthcare corporate boardrooms. Yet, for more than half the population, that promise routinely fractures. In the latest episode of the Hear...
Why faster trials make participant understanding more important than ever
White Papers and Resources | July 15, 2026 | Cuttsy + Cuttsy
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization
Press Releases | July 14, 2026 | Real Chemistry
The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value
Older trial participants reject bad design, not technology
White Papers and Resources | July 8, 2026 | Cuttsy + Cuttsy
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.